Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис:
http://hdl.handle.net/20.500.12188/33444
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Spasovski, Goce | en_US |
dc.contributor.author | Trajcheska, Lada | en_US |
dc.contributor.author | Rambabova Bushljetic, Irena | en_US |
dc.date.accessioned | 2025-05-08T12:41:29Z | - |
dc.date.available | 2025-05-08T12:41:29Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.12188/33444 | - |
dc.description.abstract | Although early rejection episodes are successfully controlled, the problem of unrecognized production of de novo anti-HLA antibodies and associated chronic rejection still persists. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Informa UK Limited | en_US |
dc.relation.ispartof | Expert Opinion on Pharmacotherapy | en_US |
dc.subject | kidney transplantation | en_US |
dc.subject | calcineurin inhibitors | en_US |
dc.subject | belatacept | en_US |
dc.subject | everolimus | en_US |
dc.subject | sirolimus | en_US |
dc.subject | eculizumab | en_US |
dc.subject | clazakizumab | en_US |
dc.subject | tocilizumab | en_US |
dc.title | Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1080/14656566.2022.2102418 | - |
dc.identifier.url | https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2102418 | - |
dc.identifier.volume | 23 | - |
dc.identifier.issue | 12 | - |
dc.identifier.fpage | 1397 | - |
dc.identifier.lpage | 1412 | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Faculty of Medicine | - |
crisitem.author.dept | Faculty of Medicine | - |
crisitem.author.dept | Faculty of Medicine | - |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.